No Data
The core executive team of SISRAM MED visited Xingrong Plastic Surgery to discuss building an innovative highland for medical beauty production, academia, research, and medicine.
Hong Kong April 23, 2025 /PR Newswire/ -- On April 22, 2025, the core executive team of SISRAM MEDICAL TECHNOLOGY CO., LTD. (referred to as "Sisram") visited FOSUN PHARMA's flagship health and beauty brand, Chongqing Xingrong Plastic Surgery Hospital (hereinafter referred to as "Xingrong Plastic Surgery"). The visiting executive team members included: Liu Yi, Senior Vice President of FOSUN PHARMA and Chairman of SISRAM MEDICAL TECHNOLOGY, CEO Lior Dayan, Chief Marketing and Strategic Officer Tal Burgan Rosen, and President of China.
SISRAM MED: 2024 ANNUAL REPORT
The industry is hotly discussing the future trends of nuclear medicine, will Hybrid NewCo become a new model for the RDC Industry to venture abroad? | Industry Observation
① Today, the 2025 Future XDC New Drug Conference is held in Chengdu; ② Executives from companies such as Baillie Tianheng and Kelun Botai, along with numerous experts and scholars in the industry, will jointly discuss cutting-edge technologies in ADC/nuclear drug development, overseas strategies, and other Topics.
Everbright: Import substitution is expected to accelerate, pay attention to the rising market share of domestic surgical robots.
Everbright stated that the import substitution is expected to accelerate, paying attention to the rise in market share of domestic surgical robots.
Sisram Medical (HKG:1696) Will Want To Turn Around Its Return Trends
China Securities Co.,Ltd.: It is recommended to focus on the new growth and integration opportunities in the Industry.
China Securities Co.,Ltd. remains bullish on high-quality Innovative Drugs companies in 2025 and actively focuses on cutting-edge technologies in pharmaceuticals and medical devices.
Not Many Are Piling Into Sisram Medical Ltd (HKG:1696) Stock Yet As It Plummets 27%
